CRTHF News and Press, Crest Nicholson Holdings PLC

2024-06-06 09:07:10 ET Summary AstraZeneca PLC showcased projects in two plenary lecture presentations at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, including a trial that established osimertinib as the standard of care for EGFR-mutant NSCLC. Bristol...

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

2024-01-21 01:55:00 ET Summary Lee’s Pharm acquired China rights to a heart failure therapy from Windtree Therapeutics. AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech Development Zone to build a new production line in its ...

2023-08-21 08:02:00 ET More on Moderna Moderna: Buy Before The Fall Covid-19 Wave Moderna Falling As Vaccine Hesitancy Rises Moderna, Inc. ( MRNA ) Q2 2023 Earnings Call Transcript Moderna, Inc. 2023 Q2 - Results - Earnings Call Presentation Moder...

2023-05-21 09:05:00 ET Summary Shanghai’s LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million (including $55 million upfront) plus royalties on sales. Suzhou Coherent Biopharma closed a Series B+ round...

Summary Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. CS Pharmaceuticals entered a $336 million agreement for greater China rights to a PRS inhibitor, Bersipo...

Summary Shanghai Mabwell Biosciences out-licensed global rights (ex-China) for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Aprinoia Therapeutics, a company developing products for neurodegenerative diseases, agreed to merge with SPAC Ross Acquisi...

Nanjing InxMed announced a $15 million B+ funding round to develop its novel therapies that target the stroma microenvironment and drug resistance for hard-to-treat solid tumors. InxMed will use the funds for US/China clinical trials of its lead drug, IN10018. US-based Coherus Bioscie...

Source : Author Editor's Note : The summary bullets for this article were chosen by Read more ...

The share price of British builder Crest Nicholson (CRTHF) (CRNHY) has been in the doldrums lately after announcing a first-half loss and likely job losses . But, despite that, its future looks secure, and now is a good time to have a look at the shares. Crest Nicholson: A Focused, Easy to ...